Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease

Neurobiology of Aging

Volumn 35, Issue SUPPL.2, 2014, Pages

  Poirier, Judes ^a,b,c   Miron, Justin ^a,b,c   Picard, Cynthia ^a,b,c   Gormley, Patrick ^a,b,c   Théroux, Louise ^a,b,c   Breitner, John ^a,b,c   Dea, Doris ^a,b,c  

^a Centre for Studies on the Prevention of Alzheimer's disease   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cholesterol; Genetics; Lipids; Probucol; Statins

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BEXAROTENE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; PROBUCOL; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); HYPOCHOLESTEROLEMIC AGENT; PEPTIDE FRAGMENT; TAU PROTEIN;

ALLELE; ALZHEIMER DISEASE; APOE GENE; BRAIN BLOOD VESSEL; CHOLESTEROL TRANSPORT; DRUG MECHANISM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LIPID HOMEOSTASIS; LIPID METABOLISM; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; DRUG EFFECT; GENE TARGETING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; MOLECULAR EVOLUTION; MOLECULAR PATHOLOGY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT PLANNING; BRAIN; CEREBROSPINAL FLUID; DEFICIENCY; DRUG EFFECTS; FEMALE; GENETICS; HOMEOSTASIS; MALE; METABOLISM; PHOSPHORYLATION;

ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; FEMALE; GENETIC ASSOCIATION STUDIES; HOMEOSTASIS; HUMANS; LIPID METABOLISM; MALE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROBUCOL; TAU PROTEINS;

EID: 84903715152     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.03.037     Document Type: Review

References (80)

1. Aleong R., Aumont N., Dea D., Poirier J. Non-steroidal anti-inflammatory drugs mediate increased invitro glial expression of apolipoprotein E protein. Eur. J. Neurosci. 2003, 18:1428-1438.
2. 2010 Alzheimer's disease facts and figures. Alzheimers Dement. 2010, 6:158-194. Alzheimer's Association (US).
3. Annapurna V., Senciall I., Davis A.J., Kutty K.M. Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats. Diabetologia 1991, 34:320-324.
4. Arendt T., Schindler C., Bruckner M.K., Eschrich K., Bigl V., Zedlick D., Marcova L. Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J.Neurosci. 1997, 17:516-529.
5. Bales K.R., Liu F., Wu S., Lin S., Koger D., DeLong C., Hansen J.C., Sullivan P.M., Paul S.M. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J.Neurosci. 2009, 29:6771-6779.
6. Beffert U., Cohn J.S., Petit-Turcotte C., Tremblay M., Aumont N., Ramassamy C., Davignon J., Poirier J. Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res. 1999, 843:87-94.
7. Beffert U., Danik M., Krzywkowski P., Ramassamy C., Berrada F., Poirier J. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res. Rev. 1998, 27:119-142.
8. Beffert U., Stolt P.C., Herz J. Functions of lipoprotein receptors in neurons. J.Lipid Res. 2003, 45:403-409.
9. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39:17-23.
10. Bertrand P., Poirier J., Oda T., Finch C.E., Pasinetti G.M. Association of apolipoprotein-E genotype with brain levels of apolipoprotein-E and apolipoprotein J in Alzheimer's disease. Mol. Brain Res. 1995, 33:174-178.
11. Bettermann K., Arnold A.M., Williamson J., Rapp S., Sink K., Toole J.F., Carlson M.C., Yasar S., Dekosky S., Burke G.L. Statins, risk of dementia, and cognitive function: secondary analysis of the Ginkgo evaluation of memory study. J.Stroke Cerebrovasc. Dis. 2011, 21:436-444.
12. Blanche H., Cabanne L., Sahbatou M., Thomas G. Astudy of French centenarians: are ACE and APOE associated with longevity?. C.R. Acad. Sci. III 2001, 324:129-135.
13. Brecht W.J., Harris F.M., Chang S., Tesseur I., Yu G.Q., Xu Q., Dee F.J., Wyss-Coray T., Buttini M., Mucke L., Mahley R.W., Huang Y. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J.Neurosci. 2004, 24:2527-2534.
14. Champagne D., Dupuy J.B., Rochford J., Poirier J. Apolipoprotein E knockout mice display procedural deficits in the Morris water maze: analysis of learning strategies in three versions of the task. Neuroscience 2002, 114:641-654.
15. Champagne D., Pearson D., Dea D., Rochford J., Poirier J. The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. Neuroscience 2003, 121:99-110.
16. Champagne D., Rochford J., Poirier J. Effect of apolipoprotein E deficiency on reactive sprouting in the dentate gyrus of the hippocampus following entorhinal cortex lesion: role of the astroglial response. Exp. Neurol. 2005, 194:31-42.
17. Chapman S., Sabo T., Roses A.D., Michaelson D.M. Reversal of presynaptic deficits of apolipoprotein E-deficient mice in human apolipoprotein E transgenic mice. Neuroscience 2000, 97:419-424.
18. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell P.C.J., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 1994, 7:180-184.
19. Craig M.C., Maki P.M., Murphy D.G. The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol. 2005, 4:190-194.
20. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., Casali B.T., Restivo J.L., Goebel W.D., James M.J., Brunden K.R., Wilson D.A., Landreth G.E. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
21. Cruchaga C., Kauwe J.S.K., Nowotny P., Bales K., Pickering E.H., Mayo K., Bertelsen S., Hinrichs A., Fagan A.M., Holtzman D.M., Morris J.C., Goate A.M. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum. Mol. Genet. 2012, 21:4558-4571. Alzheimer's Disease Neuroimaging Initiative.
22. Davignon J., Lussier-Cacan S., Dubreuil-Quidoz S., LeLorier J. Experience with probucol in the treatment of hypercholesterolemia. Artery 1982, 10:48-55.
23. Finch C.E. Evolution of the human lifespan, past, present, and future: phases in the evolution of human life expectancy in relation to the inflammatory load. Proc. Am. Philos. Soc. 2012, 156:9-44.
24. Finch C.E., Sapolsky R.M. The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms. Neurobiol. Aging 1999, 20:407-428.
25. Fitz N.F., Cronican A.A., Lefterov I., Koldamova R. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2013, 340:924.
26. Friedman G., Froom P., Sazbon L., Grinblatt I., Shochina M., Tsenter J., Babaey S., Yehuda B., Groswasser Z. Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 1999, 52:244-248.
27. Frisoni G.B., Louhija J., Geroldi C., Trabucchi M. Longevity and the epsilon2 allele of apolipoprotein E: the Finnish Centenarians Study. J.Gerontol. A Biol. Sci. Med. Sci. 2001, 56:M75-M78.
28. Fullerton S.M., Clark A.G., Weiss K.M., Nickerson D.A., Taylor S.L., Stengard J.H., Salomaa V., Vartiainen E., Perola M., Boerwinkle E., Sing C.F. Apolipoprotein E variation at the sequence haplotype level: implications for the origin and maintenance of a major human polymorphism. Am. J. Hum. Genet. 2000, 67:881-900.
29. Genin E., Hannequin D., Wallon D., Sleegers K., Hiltunen M., Combarros O., Bullido M.J., Engelborghs S., De D.P., Berr C., Pasquier F., Dubois B., Tognoni G., Fievet N., Brouwers N., Bettens K., Arosio B., Coto E., Del Z.M., Mateo I., Epelbaum J., Frank-Garcia A., Helisalmi S., Porcellini E., Pilotto A., Forti P., Ferri R., Scarpini E., Siciliano G., Solfrizzi V., Sorbi S., Spalletta G., Valdivieso F., Vepsalainen S., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Hanon O., Piccardi P., Annoni G., Seripa D., Galimberti D., Licastro F., Soininen H., Dartigues J.F., Kamboh M.I., Van B.C., Lambert J.C., Amouyel P., Campion D. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol. Psychiatry 2011, 16:903-907.
30. Giacobini E. Cholinesterases and Cholinesterase Inhibitors. Basic, Preclinical and Clinical Aspects 2000, Martin Dunitz, London.
31. Glockner F., Meske V., Ohm T.G. Genotype-related differences of hippocampal apolipoprotein E levels only in early stages of neuropathological changes in Alzheimer's disease. Neuroscience 2002, 114:1103-1114.
32. Gordon I., Genis I., Grauer E., Sehayek E., Michaelson D.M. Biochemical and cognitive studies of apolipoprotein-E-deficient mice. Mol. Chem. Neuropathol. 1996, 28:97-103.
33. Gupta V.B., Laws S.M., Villemagne V.L., Ames D., Bush A.I., Ellis K.A., Lui J.K., Masters C., Rowe C.C., Szoeke C., Taddei K., Martins R.N. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology 2011, 76:1091-1098.
34. Hanlon C.S., Rubinsztein D.C. Arginine residues at codons 112 and 158 in the apolipoprotein E gene correspond to the ancestral state in humans. Atherosclerosis 1995, 112:85-90.
35. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van B.C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
36. Herz J., Beffert U. Apolipoprotein E receptors: linking brain development and Alzheimer's disease. Nat. Rev. Neurosci. 2000, 1:51-58.
37. Hogh P., Oturai A., Schreiber K., Blinkenberg M., Jorgensen O.S., Ryder L., Paulson O.B., Sorensen P., Knudsen G.M. Apoliprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult. Scler. 2000, 6:226-230.
38. Iwasaki T., Yoneda M., Nakajima A., Terauchi Y. Serum butyrylcholinesterase is strongly associated with adiposity, the serum lipid profile and insulin resistance. Intern. Med. 2007, 46:1633-1639.
39. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
40. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
41. Kleifeld O., Diebler M.F., Chapman S., Oron L., Michaelson D.M. The effects of apolipoprotein E deficiency on brain cholinergic neurons. Int. J. Develop. Neurosci. 1998, 16:755-762.
42. Krzywkowski P., Ghribi O., Gagne J., Chabot C., Kar S., Rochford J., Massicotte G., Poirier J. Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice. Neuroscience 1999, 92:1273-1286.
43. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De D.P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van B.C., Alperovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099.
44. Leduc V., Jasmin-Belanger S., Poirier J. APOE and cholesterol homeostasis in Alzheimer's disease. Trends Mol. Med. 2010, 16:469-477.
45. Li Y.J., Hauser M.A., Scott W.K., Martin E.R., Booze M.W., Qin X.J., Walter J.W., Nance M.A., Hubble J.P., Koller W.C., Pahwa R., Stern M.B., Hiner B.C., Jankovic J., Goetz C.G., Small G.W., Mastaglia F., Haines J.L., Pericak-Vance M.A., Vance J.M. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology 2004, 62:2005-2009.
46. Lichtman S.W., Seliger G., Tycko B., Marder K. Apolipoprotein E and functional recovery from brain injury following postacute rehabilitation. Neurology 2000, 55:1536-1539.
47. May P.C., Lampert-Etchells M., Johnson S.A., Poirier J., Masters J.N., Finch C.E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 1990, 5:831-839.
48. McMahon H.T., Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 2011, 12:517-533.
49. McPherson R., Hogue M., Milne R.W., Tall A.R., Marcel Y.L. Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. Arterioscler. Thromb. 1991, 11:476-481.
50. Nicoll J.A., Roberts G.W., Graham D.I. Amyloid beta-protein, APOE genotype and head injury. Ann. N.Y. Acad. Sci. 1996, 777:271-275.
51. Oitzl M.S., Mulder M., Lucassen P.J., Havekes L.M., Grootendorst J., deKloet E.R. Severe learning deficits in apolipoprotein E knockout mice in a water maze task. Brain Res. 1997, 752:189-196.
52. Pallebage-Gamarallage M., Galloway S., Takechi R., Dhaliwal S., Mamo J. Probucol suppresses enterocytic accumulation of amyloid-β induced by saturated fat and cholesterol feeding. Lipids 2012, 47:27-34.
53. Panza F., Solfrizzi V., Colacicco A.M., Basile A.M., D'Introno A., Capurso C., Sabba M., Capurso S., Capurso A. Apolipoprotein E (APOE) polymorphism influences serum APOE levels in Alzheimer's disease patients and centenarians. Neuroreport 2003, 14:605-608.
54. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994, 17:525-530.
55. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Med. 2003, 9:94-101.
56. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol. Aging 2005, 26:355-361.
57. Poirier J. Apolipoprotein E represents a potent gene-based therapeutic target for the treatment of sporadic Alzheimer's disease. J.Alzheimers. Dement. 2008, 4:S91-S97.
58. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993, 342:697-699.
59. Poirier J., Delisle M.C., Quirion R., Aubert I., Farlow M., Lahiri D., Hui S., Bertrand P., Nalbantoglu J., Gilfix B.M., Gauthier S. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:12260-12264.
60. Poirier J., Hess M., May P.C., Finch C.E. Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning. Brain Res. Mol. Brain Res. 1991, 11:97-106.
61. Poirier J., Panisset M. Apolipoprotein E: a novel therapeutic target for the treatment of Alzheimer's disease. Adv. Exp. Med. Biol. 2002, 51:36-42.
62. Quinet E.M., Huerta P., Nancoo D., Tall A.R., Marcel Y.L., McPherson R. Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence. J.Lipid Res. 1993, 34:845-852.
63. Ramanan V.K., Risacher S.L., Nho K., Kim S., Swaminathan S., Shen L., Foroud T.M., Hakonarson H., Huentelman M.J., Aisen P.S., Petersen R.C., Green R.C., Jack C.R., Koeppe R.A., Jagust W.J., Weiner M.W., Saykin A.J. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Mol. Psychiatry 2014, 19:351-357.
64. Riddell D.R., Zhou H., Comery T.A., Kouranova E., Lo C.F., Warwick H.K., Ring R.H., Kirksey Y., Aschmies S., Xu J., Kubek K., Hirst W.D., Gonzales C., Chen Y., Murphy E., Leonard S., Vasylyev D., Oganesian A., Martone R.L., Pangalos M.N., Reinhart P.H., Jacobsen J.S. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell Neurosci. 2007, 34:621-628.
65. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W., Zalinski J., Cofield M., Mansukhani L., Willson P. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993, 43:1609-1611.
66. Santos D.B., Peres K.C., Ribeiro R.P., Colle D., dos Santos A.A., Moreira E.L., Souza D.O., Figueiredo C.P., Farina M. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid beta peptide in mice. Exp. Neurol. 2012, 233:767-775.
67. Seshadri S., Fitzpatrick A.L., Ikram M.A., DeStefano A.L., Gudnason V., Boada M., Bis J.C., Smith A.V., Carassquillo M.M., Lambert J.C., Harold D., Schrijvers E.M., Ramirez-Lorca R., Debette S., Longstreth W.T., Janssens A.C., Pankratz V.S., Dartigues J.F., Hollingworth P., Aspelund T., Hernandez I., Beiser A., Kuller L.H., Koudstaal P.J., Dickson D.W., Tzourio C., Abraham R., Antunez C., Du Y., Rotter J.I., Aulchenko Y.S., Harris T.B., Petersen R.C., Berr C., Owen M.J., Lopez-Arrieta J., Varadarajan B.N., Becker J.T., Rivadeneira F., Nalls M.A., Graff-Radford N.R., Campion D., Auerbach S., Rice K., Hofman A., Jonsson P.V., Schmidt H., Lathrop M., Mosley T.H., Au R., Psaty B.M., Uitterlinden A.G., Farrer L.A., Lumley T., Ruiz A., Williams J., Amouyel P., Younkin S.G., Wolf P.A., Launer L.J., Lopez O.L., van Duijn C.M., Breteler M.M. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303:1832-1840.
68. Slooter A.J., Tang M.X., van Duijn C.M., Stern Y., Ott A., Bell K., Breteler M.M., Van B.C., Tatemichi T.K., Tycko B., Hofman A., Mayeux R. Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. JAMA 1997, 277:818-821.
69. Soares H.D., Potter W.Z., Pickering E., Kuhn M., Immermann F.W., Shera D.M., Ferm M., Dean R.A., Simon A.J., Swenson F., Siuciak J.A., Kaplow J., Thambisetty M., Zagouras P., Koroshetz W.J., Wan H.I., Trojanowski J.Q., Shaw L.M. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch. Neurol. 2012, 69:1310-1317.
70. Sorbi S., Nacmias B., Piacentini S., Repice A., Latorraca S., Forleo P., Amaducci L. ApoE as a prognostic factor for post-traumatic coma. Nat. Med. 1995, 1:852.
71. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A 1993, 90:8098-8102.
72. Sullivan P.M., Han B., Liu F., Mace B.E., Ervin J.F., Wu S., Koger D., Paul S., Bales K.R. Reduced levels of human apoE4 protein in an animal model of cognitive impairment. Neurobiol. Aging 2009, 32:791-801.
73. Utermann G. Apolipoprotein E mutants, hyperlipidemia and arteriosclerosis. Adv. Exp. Med. Biol. 1985, 183:173-188.
74. Utermann G., Langenbeck U., Beisiegel U., Weber W. Genetics of the apolipoprotein E system in man. Am. J. Hum. Genet. 1980, 32:339-347.
75. Van Uden E., Sagara Y., Van Uden J., Orlando R., Mallory M., Rockenstein E., Masliah E. Aprotective role of the low density lipoprotein receptor-related protein against amyloid beta-protein toxicity. J.Biol. Chem. 2000, 275:30525-30530.
76. Veinbergs I., Mallory M., Mante M., Rockenstein E., Gilbert J.R., Masliah E. Differential neurotrophic effects of apolipoprotein E in aged transgenic mice. Neurosci. Lett. 1999, 265:218-222.
77. Veinbergs I., Masliah E. Synaptic alterations in apolipoprotein E knockout mice. Neuroscience 1999, 91:401-403.
78. Wilmoth J.R. Demography of longevity: past, present, and future trends. Exp. Gerontol. 2000, 35:1111-1129.
79. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57:1439-1443.
80. Wolozin B., Wang S.W., Li N.C., Lee A., Lee T.A., Kazis L.E. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007, 5:20.